概括
对于没有驱动突变的高级非小细胞肺癌患者,需要新的治疗指南. 这个专家小组审查了证据,以指导当初治疗失败时的二线治疗选择.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 临床医学 临床医学
背景情况:
- 具有负驱动突变的高级非小细胞肺癌 (NSCLC) 传统上依赖于化疗.
- 免疫检查点抑制剂 (ICI) 提供了一个替代方案,但疾病进展很常见.
- 目前的二线和后续治疗NSCLC的疗效有限,需要改进治疗选择.
研究的目的:
- 为中国临床医生提供基于证据的指导,帮助他们选择高级NSCLC患者的二线治疗方法,这些患者具有负驱动基因突变.
- 为了解决对这种患者群体更有效治疗的未满足的临床需求.
主要方法:
- 召开了一个由呼吸系统医学,病理学和医疗瘤学专家组成的专家小组.
- 专家小组进行了深入的讨论和对临床研究证据的审查.
- 重点是针对负驱动基因突变的NSCLC患者的二线治疗策略.
主要成果:
- 化疗,抗血管性药物和免疫疗法是目前高级NSCLC的第一线选择.
- 尽管最初有效,但疾病的进展和治疗失败是不可避免的.
- 证据支持需要优化二线治疗选择.
结论:
- 专家一致认为,在先进的NSCLC中,急需有效的二线治疗.
- 提供指导,以帮助临床医生在第一线治疗失败后选择最佳疗法.
- 进一步研究和开发新药对于改善这一患者群体的治疗结果至关重要.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
